Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 7;17(29):3448-52.
doi: 10.3748/wjg.v17.i29.3448.

Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure

Kun Huang  1 , Jin-Hua Hu, Hui-Fen Wang, Wei-Ping He, Jing Chen, Xue-Zhang Duan, Ai-Min Zhang, Xiao-Yan Liu
Affiliations

Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure

Kun Huang et al. World J Gastroenterol. .

Abstract

Aim: To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).

Methods: Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed. Their general conditions and survival were analyzed by survival analysis and Cox regression analysis.

Results: A total of 190 patients were included in this study. The overall 1-year survival rate was 57.6%. Patients not treated with antiviral drugs had a significantly higher mortality [relative risk (RR) = 0.609, P = 0.014]. The highest risk of death in patients with ACLF was associated with hepatorenal syndrome (HRS) (RR = 2.084, P =0.026), while other significant factors were electrolyte disturbances (RR = 2.062, P = 0.010), and hepatic encephalopathy (HE) (RR = 1.879, P < 0.001).

Conclusion: Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate. HRS, electrolyte disturbances, and HE also affect patient survival.

Keywords: Acute-on-chronic liver failure; Antiviral therapy; Hepatitis B virus; Nucleosides; Survival analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curves for patients taking or not taking antiviral drugs by Kaplan-Meier method. Total, n = 190; antiviral drugs, n = 141; no antiviral drugs, n = 49.
Figure 2
Figure 2
Survival curves for the entecavir and lamivudine groups by Kaplain-Meier method. Total, n = 141; entecavir group, n = 77; lamivudine group, n = 64.
See this image and copyright information in PMC

References

    1. Merle P, Trépo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging. 2001;18:725–735. - PubMed
    1. Li XM, Ma L, Yang YB, Shi ZJ, Zhou SS. Analyses of prognostic indices of chronic liver failure caused by hepatitis virus. World J Gastroenterol. 2005;11:2841–2843. - PMC - PubMed
    1. Liu Q, Liu Z, Wang T, Wang Q, Shi X, Dao W. Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol. 2007;22:2101–2106. - PubMed
    1. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Diagnostic and treatment guidelines for liver failure] Zhonghua Ganzangbing Zazhi. 2006;14:643–646. - PubMed
    1. Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, Rosen CB, Thostenson J, Benson JT, Dickson ER. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant. 2004;4:1798–1804. - PubMed

Publication types

MeSH terms

Substances